Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non-muscle-invasive Bladder Cancer Refractory to Standard Intravesical Therapy

Urology

Volumn 75, Issue 1, 2010, Pages 134-137

  Laudano, Melissa A ^a   Barlow, Lamont J ^a   Murphy, Alana M ^a   Petrylak, Daniel P ^a   Desai, Manisha ^b   Benson, Mitchell C ^a   McKiernan, James M ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Public Health Columbia University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; CYTOLOGY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TAXOIDS; TIME FACTORS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 72249096707     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.112     Document Type: Article

References (12)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Fitzpatrick J.M., West A.B., Butler M.R., et al. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135 (1986) 920-922
3. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083-1086
4. Lamm D.L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134 (1985) 40-47
5. Kolodziej A., Dembowski J., Zdrojowy R., et al. Treatment of high-risk superficial bladder cancer with maintenance Bacille Calmette-Guerin therapy: preliminary results. BJU Int 89 (2002) 620-622
6. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol 132 (1984) 457-459
7. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 147 (1992) 1020-1023
8. McKiernan J.M., Masson P., Murphy A.M., et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24 (2006) 3075-3080
9. Rangel C., Niell H., Miller A., et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33 (1994) 460-464
10. Catalona W.J., Hudson M.A., Gillen D.P., et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137 (1987) 220-224
11. Greenberg R.E., Bahnson R.R., Wood D., et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49 (1997) 471-475
12. Malmstrom P.U., Wijkstrom H., Lundholm C., et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127